Seema Naik, MD

Penn State Cancer Institute

Disclosure(s): ADC Therapeutics: Advisor/Consultant, Board Member, Honoraria; Janssen: Advisor/Consultant, Board Member, Honoraria; Onclive: Honoraria, Speaker

Poster(s):

• (P-2258) Characterizing real world infection risk in multiple myeloma patients receiving teclistamab
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT